Seattle Genetics, Inc., Takeda Pharmaceutical Co. Ltd. and Millennium: The Takeda Oncology Company Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma

BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN), Takeda Pharmaceutical Company Limited (TOKYO:4502) and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of a phase III clinical trial of brentuximab vedotin (SGN-35) for post-transplant Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, which is expressed on malignant Hodgkin lymphoma cells. The phase III trial, also known as AETHERA, will evaluate brentuximab vedotin versus placebo for the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant (ASCT).